Analysis of TGF-? traps as effective immunostimulating cancer treatments

AVID200 is a TGF-? trap that specifically sequesters TGF-?I and TGF-?III to enhance antitumour immunity to inhibit tumor growth. AVID200 also avoids adverse side effect of depleted of TGF-?II. AVID200 is relatively short-lived in circulation, decreasing its capacity to exert desirable enhancement of anti-tumour immunity. To increase the effectiveness of TGF-? traps, a panel of candidate molecules that retain TGF-? isoform specificity and inactivating capacity, but with projected increased stability, have been generated by Formation Biologics.

Development of a novel robust clone for the manufacturing of AVID100 biosimilar

AVID100 is an antibody-drug conjugate (ADC) against a validated cancer target that is undergoing IND-enabling studies. Phase I clinical trials are scheduled for late 2016. The monoclonal antibody (mAb) portion of the ADC is currently manufactured using a recombinant CHO clone that fails to meet industrial production yield standards. In order to support clinical phases II and III as well as commercial supply a higher-expressing cell line must be developed. MAb product characteristics will need to be similar to the current clone, namely with regards to the N-glycan composition.